克拉霉素治疗儿童肉芽肿性周周皮炎:一项回顾性队列研究

IF 5.2
Yizhu Xiao PhD, Jingyi He PhD, Anwei Chen MD, Xiao Fang MD, Ping Tang MD, Juan Xiang PhD
{"title":"克拉霉素治疗儿童肉芽肿性周周皮炎:一项回顾性队列研究","authors":"Yizhu Xiao PhD,&nbsp;Jingyi He PhD,&nbsp;Anwei Chen MD,&nbsp;Xiao Fang MD,&nbsp;Ping Tang MD,&nbsp;Juan Xiang PhD","doi":"10.1016/j.jdin.2025.08.005","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>Childhood granulomatous periorificial dermatitis incidence is increasing, yet topical therapies remain suboptimal with chronicity and scarring risks in severe cases. Systemic alternatives are urgently needed. Although oral clarithromycin shows promise, its efficacy/safety evidence in pediatric populations lacks robustness.</div></div><div><h3>Objective</h3><div>This study evaluated the effect of clarithromycin on a pediatric group with granulomatous periorificial dermatitis.</div></div><div><h3>Methods</h3><div>This retrospective study analyzed 43 patients treated with oral clarithromycin, with outcomes including treatment efficacy, adverse event incidence, and scar incidence.</div></div><div><h3>Results</h3><div>All patients completed clarithromycin therapy (median 10 weeks; 2-26). At 6 months, 95.4% (41/43) cleared, with 2.3% each recurrence and nonresponse. Treatment duration correlated with both baseline severity (<em>r</em> = 0.592, <em>P</em> &lt; .01) and disease duration (<em>r</em> = 0.590, <em>P</em> &lt; .01). Scarring (14.6%) occurred only in moderate-to-severe cases, which showed greater severity (<em>P</em> = .039) and longer courses (<em>P</em> = .028). No severe adverse events occurred.</div></div><div><h3>Limitations</h3><div>This is a retrospective study without case controls and is subject to interviewer and memory bias.</div></div><div><h3>Conclusion</h3><div>For moderate-to-severe or stubborn cases, timely evaluation and tailored systemic interventions are critical to mitigate scarring risks. Clarithromycin is an effective and tolerated therapy in children with moderate-to-severe and refractory granulomatous periorificial dermatitis.</div></div>","PeriodicalId":34410,"journal":{"name":"JAAD International","volume":"23 ","pages":"Pages 48-54"},"PeriodicalIF":5.2000,"publicationDate":"2025-08-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Management of childhood granulomatous periorificial dermatitis with clarithromycin: A retrospective cohort study\",\"authors\":\"Yizhu Xiao PhD,&nbsp;Jingyi He PhD,&nbsp;Anwei Chen MD,&nbsp;Xiao Fang MD,&nbsp;Ping Tang MD,&nbsp;Juan Xiang PhD\",\"doi\":\"10.1016/j.jdin.2025.08.005\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Background</h3><div>Childhood granulomatous periorificial dermatitis incidence is increasing, yet topical therapies remain suboptimal with chronicity and scarring risks in severe cases. Systemic alternatives are urgently needed. Although oral clarithromycin shows promise, its efficacy/safety evidence in pediatric populations lacks robustness.</div></div><div><h3>Objective</h3><div>This study evaluated the effect of clarithromycin on a pediatric group with granulomatous periorificial dermatitis.</div></div><div><h3>Methods</h3><div>This retrospective study analyzed 43 patients treated with oral clarithromycin, with outcomes including treatment efficacy, adverse event incidence, and scar incidence.</div></div><div><h3>Results</h3><div>All patients completed clarithromycin therapy (median 10 weeks; 2-26). At 6 months, 95.4% (41/43) cleared, with 2.3% each recurrence and nonresponse. Treatment duration correlated with both baseline severity (<em>r</em> = 0.592, <em>P</em> &lt; .01) and disease duration (<em>r</em> = 0.590, <em>P</em> &lt; .01). Scarring (14.6%) occurred only in moderate-to-severe cases, which showed greater severity (<em>P</em> = .039) and longer courses (<em>P</em> = .028). No severe adverse events occurred.</div></div><div><h3>Limitations</h3><div>This is a retrospective study without case controls and is subject to interviewer and memory bias.</div></div><div><h3>Conclusion</h3><div>For moderate-to-severe or stubborn cases, timely evaluation and tailored systemic interventions are critical to mitigate scarring risks. Clarithromycin is an effective and tolerated therapy in children with moderate-to-severe and refractory granulomatous periorificial dermatitis.</div></div>\",\"PeriodicalId\":34410,\"journal\":{\"name\":\"JAAD International\",\"volume\":\"23 \",\"pages\":\"Pages 48-54\"},\"PeriodicalIF\":5.2000,\"publicationDate\":\"2025-08-29\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"JAAD International\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S266632872500094X\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"JAAD International","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S266632872500094X","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

儿童肉芽肿性周周皮炎的发病率正在增加,但局部治疗仍然不理想,严重情况下存在慢性和瘢痕形成风险。我们迫切需要系统性的替代方案。尽管口服克拉霉素显示出前景,但其在儿科人群中的有效性/安全性证据缺乏可靠性。目的评价克拉霉素治疗小儿肉芽肿性周周皮炎的疗效。方法回顾性分析43例口服克拉霉素患者的治疗效果、不良事件发生率和疤痕发生率。结果所有患者均完成克拉霉素治疗(中位10周;2-26周)。6个月时,95.4%(41/43)患者痊愈,2.3%复发且无反应。治疗时间与基线严重程度(r = 0.592, P < 0.01)和病程(r = 0.590, P < 0.01)相关。瘢痕形成(14.6%)仅发生在中重度病例,其严重程度较高(P = 0.039),病程较长(P = 0.028)。未发生严重不良事件。局限性:这是一项没有病例对照的回顾性研究,容易受到采访者和记忆偏差的影响。结论对于中重度或顽固病例,及时评估和有针对性的系统干预是减轻瘢痕形成风险的关键。克拉霉素是一种有效和耐受性治疗儿童中重度难治性肉芽肿性周周皮炎。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Management of childhood granulomatous periorificial dermatitis with clarithromycin: A retrospective cohort study

Background

Childhood granulomatous periorificial dermatitis incidence is increasing, yet topical therapies remain suboptimal with chronicity and scarring risks in severe cases. Systemic alternatives are urgently needed. Although oral clarithromycin shows promise, its efficacy/safety evidence in pediatric populations lacks robustness.

Objective

This study evaluated the effect of clarithromycin on a pediatric group with granulomatous periorificial dermatitis.

Methods

This retrospective study analyzed 43 patients treated with oral clarithromycin, with outcomes including treatment efficacy, adverse event incidence, and scar incidence.

Results

All patients completed clarithromycin therapy (median 10 weeks; 2-26). At 6 months, 95.4% (41/43) cleared, with 2.3% each recurrence and nonresponse. Treatment duration correlated with both baseline severity (r = 0.592, P < .01) and disease duration (r = 0.590, P < .01). Scarring (14.6%) occurred only in moderate-to-severe cases, which showed greater severity (P = .039) and longer courses (P = .028). No severe adverse events occurred.

Limitations

This is a retrospective study without case controls and is subject to interviewer and memory bias.

Conclusion

For moderate-to-severe or stubborn cases, timely evaluation and tailored systemic interventions are critical to mitigate scarring risks. Clarithromycin is an effective and tolerated therapy in children with moderate-to-severe and refractory granulomatous periorificial dermatitis.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
JAAD International
JAAD International Medicine-Dermatology
CiteScore
3.60
自引率
0.00%
发文量
169
审稿时长
45 days
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信